This site is intended for health professionals only
Saturday 21 April 2018
Share |

First European study of Tresiba® shows improved blood glucose control and reduced hypoglycaemia

Additional study demonstrates cost impact of hypoglycaemia in the hospital setting

New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.
 

 

Ads by Google